454,930 Shares in Evolus, Inc. $EOLS Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank AG acquired 454,930 Evolus shares in the second quarter, worth approximately $3.16 million and representing 0.69% of the company.
• Other institutional investors also increased or initiated positions, contributing to institutional ownership of 90.69% of Evolus shares.
• Evolus opened at $8.78, near its 52-week high of $9.12. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $14.50.

Deutsche Bank AG bought a new position in Evolus, Inc. (NASDAQ:EOLS - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 454,930 shares of the company's stock, valued at approximately $3,157,000. Deutsche Bank AG owned 0.69% of Evolus at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Larson Financial Group LLC raised its holdings in shares of Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock valued at $33,000 after acquiring an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Evolus during the 4th quarter valued at about $34,000. Wexford Capital LP purchased a new position in Evolus during the 3rd quarter valued at about $37,000. Aquatic Capital Management LLC bought a new stake in shares of Evolus in the 3rd quarter valued at about $48,000. Finally, State of Wyoming bought a new stake in shares of Evolus in the 4th quarter valued at about $63,000. Institutional investors own 90.69% of the company's stock.

Evolus Stock Down 2.2%

NASDAQ:EOLS opened at $8.78 on Thursday. The stock has a market capitalization of $579.92 million, a price-to-earnings ratio of -16.88 and a beta of 1.35. Evolus, Inc. has a 52 week low of $3.86 and a 52 week high of $9.12. The firm has a 50 day moving average of $6.95 and a 200 day moving average of $5.86.

Analyst Ratings Changes

A number of research firms have recently issued reports on EOLS. BTIG Research reiterated a "buy" rating and set a $13.00 price objective on shares of Evolus in a research note on Wednesday, June 17th. Weiss Ratings upgraded Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 15th. HC Wainwright reaffirmed a "buy" rating and set a $13.00 target price on shares of Evolus in a research report on Tuesday. Finally, Wall Street Zen raised Evolus from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Evolus currently has a consensus rating of "Moderate Buy" and an average target price of $14.50.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source